Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that updated phase 1 safety and efficacy data for DS-8201, an investigational HER2-targeting antibody drug conjugate …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
